Alterations of intestinal lipoprotein metabolism in diabetes mellitus and metabolic syndrome

Marcello Arca *

Dipartimento di Medicina Interna e Specialità Mediche, UOS Centro Arteriosclerosi Università di Roma La Sapienza, Rome, Italy

Abstract

Diabetes and metabolic syndrome are associated with abnormal postprandial lipoprotein metabolism, with a significant delay in the clearance of many lipid parameters, including triglycerides and chylomicrons. Abnormal concentrations of plasma lipids can result from changes in the production, conversion, or catabolism of lipoprotein particles. Whereas the liver is involved in controlling serum lipid levels through synthesis of liver derived triglyceride-rich lipoproteins and low-density lipoprotein metabolism, the intestine also has a major role in lipoprotein production. Postprandial lipemia results from increases in apoB-48 availability, lipogenesis, and the synthesis and absorption of cholesterol in the enterocytes. Increased intestinal lipoprotein production prolongs postprandial lipemia in patients with diabetes and MetS, and may contribute directly to atherogenesis in these patients.

Keywords: Diabetes mellitus; Metabolic syndrome; Intestine; Cholesterol metabolism; Postprandial lipemia

1. Abnormalities of lipoprotein metabolism in diabetes mellitus and metabolic syndrome

Dyslipidemia associated with diabetes mellitus and metabolic syndrome (MetS) is characterized by a cluster of metabolically interrelated lipoprotein abnormalities. Due to the elevated atherogenic potential of these abnormalities they are usually comprehensively designated as atherogenic dyslipidemia (AD). The phenotypic hallmarks of AD are increased plasma triglycerides (TG), reduced high-density lipoprotein cholesterol (HDL-C) and increased numbers of small, dense low-density lipoprotein (sdLDL) particles.

Abnormal concentrations of plasma lipids can result from changes in the production, conversion, or catabolism of lipoprotein particles. Therefore, several studies have investigated the kinetic parameters of apoB-containing lipoproteins [low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL)] to identify the mechanisms responsible for AD. These studies have consistently reported that the major metabolic defects in AD are increased VLDL production, and reduced catabolism of LDL and its precursor, intermediate-density lipoprotein (IDL).

Overproduction of VLDL is particularly evident in patients with diabetes, where this abnormality is related to the plasma glucose level and indices of tissue insulin sensitivity such as the HOMA index. In addition, intra-abdominal and liver fat are also significant predictors of liver production of large TG-rich VLDL [1].

Assessment of HDL metabolism in subjects with diabetes using a stable isotope method revealed a higher than normal mean fractional catabolic rate (FCR) of apoAI-HDL, strongly suggesting that HDL is catabolized more rapidly in these patients. Therefore, the AD phenotype can result from: 1) increased production of VLDL, 2) a reduced catabolic rate of apoB-containing lipoproteins (IDL and LDL), and 3) an increased catabolic rate of HDL.

The liver plays a fundamental role in cholesterol homeostasis, because it processes cholesterol taken up from plasma lipoproteins and chylomicrons, and uses cholesterol to form bile acids that are subsequently secreted into the bile. As the major site of LDL catabolism, the liver also...
has a part in determining plasma LDL levels. As described elsewhere in this supplement [2], the liver is not the only organ with an important role in this process: also the intestine plays an essential role. In diabetes mellitus or MetS, chylomicrons produced in the intestine can accumulate in the circulation thereby influencing overall lipid and lipoprotein turnover. There are indications that chylomicrons and cholesterol metabolism in the intestine are involved in regulating plasma LDL concentrations [3].

2. Abnormalities in intestinal lipids and lipoprotein metabolism in diabetes and metabolic syndrome

Patients with diabetes have abnormal post absorptive lipoprotein metabolism, with a significant delay in the postprandial clearance of many lipid parameters, including triglycerides and chylomicrons, in spite of normal fasting levels [4]. Similar results have been observed in people with MetS [5]. This is observed even if subjects are categorized according to insulin resistance.

Chylomicrons are lipoprotein particles secreted by the intestine during the postprandial period. Their assembly is a complex, multistep process (Fig. 1), in which apoB-48 synthesis is one of the limiting factors [6]. Duez et al. hypothesized that abnormalities in the synthesis of intestinally-derived apolipoproteins drive the prolonged postprandial phase in insulin-resistant subjects, and examined the relationship between insulin resistance and the rate of production of intestinal lipoproteins [7]. They found that ApoB-48 was produced at a significantly higher rate in hyperinsulinemic, insulin-resistant subjects and that this correlated with fasting plasma insulin concentrations. Consistent with this observation, others have reported that insulin administration decreases levels of circulating apoB-48-containing lipoproteins [8].

More recent evidence indicates that the adipokine resistin is also involved in regulating chylomicron assembly. Plasma resistin concentrations are elevated in MetS and associated with insulin resistance [9]. In cultured hepatocytes, resistin stimulates the overproduction of VLDL apo-B by increasing the activity of the microsomal transfer protein (MTP), which plays a pivotal role in coupling triglycerides with apoB-48 in chylomicrons (Fig. 1), and by decreasing insulin signaling [10].

Chylomicron assembly is also influenced by the availability of cholesterol in enterocytes. Regulation of chylomicron cholesterol is depicted in Fig. 2. Cholesterol is absorbed through a process facilitated by the Niemann-Pick C1-Like 1 (NPC1L1) protein, which plays the major quantitative role in intestinal cholesterol absorption. In addition, ABCG5 and ABCG8 proteins regulate enterocyte cholesterol content by promoting its re-excretion into the intestinal lumen throughout the intestinal villi.

NPC1L1 mRNA expression is elevated in patients with type 2 diabetes [11], suggesting that cholesterol absorption is increased. Moreover, these patients also have increased expression of MTP, associated with reduced expression of the cholesterol efflux transporters ABCG5 and ABCG8 (Fig. 3). Taken together, this pattern strongly support the notion that diabetic patients have elevated amounts of enterocyte cholesterol available for chylomicron assembly.

Based on these observations, one could hypothesize that the modulating intestine cholesterol metabolism might be a useful strategy for controlling the exaggerated postprandial lipemia in insulin-resistant conditions (diabetes mellitus and MetS). Ezetimibe is a compound that specifically reduces intestinal cholesterol absorption by inhibiting the activity of NPC1L1 [12]. Administration of ezetimibe to men with moderate primary hypercholesterolemia increases the fractional catabolic rate of apoB-100-containing lipoproteins.
Fig. 2. Chylomicron cholesterol derives from dietary, biliary and intestinal de novo synthesized cholesterol. NPC1-L1 regulates its absorption and ABCG5 and ABCG8 regulate its excretion. MTP assembles the apoB-48 protein, cholesterol and other lipids to form the chylomicron, which is then secreted into the lymph. (Reproduced with permission from Diabetes Care 2008 Feb;31 Suppl 2:S241–8 [6].)

Fig. 3. Comparison of mRNA expression of intestinal proteins regulating cholesterol absorption and chylomicron composition in diabetic (n=15) (black bars) and non-diabetic control patients (n=17) (white bars) not receiving statin treatment. a) microsomal triglyceride transfer protein (MTP) and Niemann-Pick C1-like 1 (NPC1-L1); b) ATP-binding cassette, transporters G5 and G8 (ABCG5/G8). Mean ± SE, *p < 0.05, **p < 0.02 compared to control subjects. (Reproduced with permission from Diabetologia 2006 May;49(5):1008–16 [11].)

with an associated decrease in this lipoprotein fraction [13], which is considered the major mechanism of action of this drug. However, several studies have demonstrated that ezetimibe has a beneficial effect also on postprandial triglyceride-rich lipoproteins in patients with type 2 diabetes. For example, postprandial chylomicron apoB-48 concentrations were about 50% lower in subjects with type 2 diabetes and hypercholesterolemia receiving simvastatin + ezetimibe, compared with simvastatin + placebo (Fig. 4) [14]. This decrease suggests that ezetimibe reduces the number of intestinal particles, confirming the results from the kinetic study in men with mixed hyperlipidemia cited above [13].

Chylomicron cholesterol content was also significantly lower after ezetimibe compared to placebo, even in the fasting state, and this difference remained statistically significant during the entire postprandial phase. Postprandial levels of chylomicron triglycerides and the cholesterol/triglyceride ratio were also significantly lower with ezetimibe, compared to placebo, as were the levels of apoB.

3. Contribution of insulin resistance-related perturbation of intestinal lipid metabolism to cardiovascular risk in patients with diabetes or metabolic syndrome

During the postprandial phase, triglyceride-rich lipoproteins (chylomicrons and VLDL) are converted into partially hydrolyzed lipoproteins known as remnant-like particles (RLPs) which represent transient lipoprotein particles rel-
to increased hepatic synthesis of liver derived triglyceride-rich lipoproteins (VLDL). These conditions are associated with increased intestinal lipoprotein production. This results from increases in apoB-48 availability, lipogenesis, and the synthesis and absorption of cholesterol in the enterocytes. Increased intestinal lipoprotein production prolongs postprandial lipemia in patients with diabetes and MetS, and may contribute directly to atherogenesis in these patients.

Disclosure

Dr. Arca received lecture honoraria, consultancy fees and research funding from Merck Sharp & Dohme, Pfizer, Asta Zeneca, Kowa, Sanofi, Regeneron, Roche, Genzyme, Abbott, Boheringer, Aegerion, Mediolanum, SigmaTau, Menarini, ISIS, Amgen.

This work was funded by an unrestricted grant by MSD Italia Srl. The sponsor had no role in reviewing the literature, drafting or reviewing the paper, or in the decision to submit the manuscript for publication. All views expressed are solely those of the author. The author would like to thank Editamed Srl for editorial assistance in the preparation of the manuscript.

References


